Dr. E. David Crawford spoke at the 23rd annual Perspectives in Urology Point • Counterpoint meeting on Saturday, November 15, 2014 on “Update of Androgen Deprivation Therapy.”

 

Keywords: prostate cancer, cardiovascular side effects, androgen deprivation therapy (ADT)

How to cite: Crawford, E. David. “Update of Androgen Deprivation Therapy” Grand Rounds in Urology. August 5, 2015. Accessed Apr 2020. https://grandroundsinurology.com/prostate-cancer-e-david-crawford-update-of-androgen-deprivation-therapy/.

References

Arcadi JA. Rapid drop in serum testosterone after bilateral subcapsular orchiectomy. J Surg Oncol. 1992 Jan;49(1):35-8.
http://www.ncbi.nlm.nih.gov/pubmed/1548879

Ben-Josef E, Yang SY, Ji TH, et al. Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR). J Urol. 1999 Mar;161(3):970-6.
http://www.ncbi.nlm.nih.gov/pubmed/10022736

Broqua P, Riviere PJ, Conn PM, et al. Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix. J Pharmacol Exp Ther. 2002 Apr;301(1):95-102.
http://www.ncbi.nlm.nih.gov/pubmed/11907162

Cassileth BR, Soloway MS, Vogelzang NJ, et al. Quality of life and psychosocial status in stage D prostate cancer. Zoladex Prostate Cancer Study Group. Qual Life Res. 1992 Oct;1(5):323-9.
http://www.ncbi.nlm.nih.gov/pubmed/1299464

Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989 Aug 17;321(7):419-24.
http://www.ncbi.nlm.nih.gov/pubmed/2503724

Crawford ED, Rove KO. Incomplete testosterone suppression in prostate cancer. N Engl J Med. 2010 Nov 11;363(20):1976.
http://www.ncbi.nlm.nih.gov/pubmed/21067409

Crawford ED, Tombal B, Miller K, et al. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J Urol. 2011 Sep;186(3):889-97.
http://www.ncbi.nlm.nih.gov/pubmed/21788033

Dansky HM, Charlton SA, Harper MM, et al. T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4642-6.
http://www.ncbi.nlm.nih.gov/pubmed/9114044

Epstein MM, Edgren G, Rider JR, et al. Temporal trends in cause of death among Swedish and US men with prostate cancer. J Natl Cancer Inst. 2012 Sep 5;104(17):1335-42.
http://www.ncbi.nlm.nih.gov/pubmed/22835388

Garde S, Sheth A, Porter AT, et al. Effect of prostatic inhibin peptide (PIP) on prostate cancer cell growth in vitro and in vivo. Prostate. 1993;22(3):225-33.
http://www.ncbi.nlm.nih.gov/pubmed/8488155

Heidenreich A, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease. Actas Urol Esp. 2011 Oct;35(9):501-14.
http://www.ncbi.nlm.nih.gov/pubmed/21757259

Kaisary AV, Tyrrell CJ, Peeling WB, et al. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol. 1991 May;67(5):502-8.
http://www.ncbi.nlm.nih.gov/pubmed/1828183

Ketchandji M, Kuo YF, Shahinian VB, et al. Cause of death in older men after the diagnosis of prostate cancer. J Am Geriatr Soc. 2009 Jan;57(1):24-30.
http://www.ncbi.nlm.nih.gov/pubmed/19054189

Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008 Dec;102(11):1531-8.
http://www.ncbi.nlm.nih.gov/pubmed/19035858

Millar RP, Lu ZL, Pawson AJ, et al. Gonadotropin-releasing hormone receptors. Endocr Rev. 2004 Apr;25(2):235-75.
http://www.ncbi.nlm.nih.gov/pubmed/15082521

Morote J, Orsola A, Planas J, et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol. 2007 Oct;178(4 Pt 1):1290-5.
http://www.ncbi.nlm.nih.gov/pubmed/17698136

Morote J, Esquena S, Abascal JM, et al. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer. Urol Int. 2006;77(2):135-8.
http://www.ncbi.nlm.nih.gov/pubmed/16888418

Nakabayashi M, Werner L, Oh WK, et al. Secondary hormonal therapy in men with castration-resistant prostate cancer. Clin Genitourin Cancer. 2011 Dec;9(2):95-103.
http://www.ncbi.nlm.nih.gov/pubmed/21958520

Oefelein MG, Feng A, Scolieri MJ, et al. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology. 2000 Dec 20;56(6):1021-4.
http://www.ncbi.nlm.nih.gov/pubmed/11113751

Røhl HF, Beuke HP. Effect of orchidectomy on serum concentrations of testosterone and dihydrotestosterone in patients with prostatic cancer. Scand J Urol Nephrol. 1992;26(1):11-4.
http://www.ncbi.nlm.nih.gov/pubmed/1631501

Seidenfeld J, Samson DJ, Hasselblad V, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med. 2000 Apr 4;132(7):566-77.
http://www.ncbi.nlm.nih.gov/pubmed/10744594

Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005 Jul 13;294(2):238-44.
http://www.ncbi.nlm.nih.gov/pubmed/16014598

Sweeney CJ. ECOG: CHAARTED-ChemoHormonal therapy versus androgen ablation randomized trial for extensive disease inprostate cancer. Clin Adv Hematol Oncol. 2006 Aug;4(8):588-90.
http://www.ncbi.nlm.nih.gov/pubmed/17111557

Thompson IM. Flare Associated with LHRH-Agonist Therapy. Rev Urol. 2001;3 Suppl 3:S10-4.
http://www.ncbi.nlm.nih.gov/pubmed/16986003

Vogelzang NJ, Chodak GW, Soloway MS, et al. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group. Urology. 1995 Aug;46(2):220-6.
http://www.ncbi.nlm.nih.gov/pubmed/7624991